Testing dual-target CAR T cells for B-cell blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests CAR T cells designed to attack B-cell blood cancers using two targets (CD19 and CD20/CD22). It may help people whose cancer has come back or not responded to standard treatments, but it is mainly to check safety and early effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a relapsed or treatment-resistant B-cell blood cancer
- Your cancer cells test positive for CD19 and also CD20 or CD22
- You are between 18 and 70 years old, and you have tumors that can be measured
- Your overall health is good enough for treatment: energy score (ECOG) 0–2 and organ tests within set limits
- You have an estimated life expectancy of more than 3 months
- If you can become pregnant, you must use birth control starting before treatment and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
This trial tests a new type of CAR T-cell therapy that targets two markers (CD19 and CD20) on B-cell cancer cells. It is for people whose B-cell leukemia or lymphoma has come back or not responded to standard treatments.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This trial tests a new type of immunotherapy called bispecific CAR T cells that target two markers (CD19 and CD20) on cancer cells. It is for people with certain B-cell blood cancers that have come back or not responded to other treatments.
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Hear when a new 19 and 22+ B Cell Hematologic Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.